摘要
目的:运用Meta分析方法系统评价PD-1/PD-L1抑制剂治疗中晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法:检索CNKI、万方、Pubmed和Cochrane图书馆数据库,提取数据并进行核对,利用RevMan5.3软件的Cochrane偏倚风险工具,对随机对照试验进行风险评估,并应用该软件进行Meta分析。结果:共纳入7个随机对照试验,包括3945例患者。Meta分析结果显示:PD-1/PD-L1抑制剂在总生存期[HR=0.66,95%CI(0.61,0.72),P<0.00001]、无进展生存期[HR=0.72,95%CI(0.59,0.87),P=0.0007]、总有效率[OR=1.91,95%CI(1.31,2.78),P=0.0007]方面均高于化疗对照组;任何级别不良反应事件[OR=0.32,95%CI(0.25,0.40),P<0.00001]和3、4、5级不良反应事件[OR=0.23,95%CI(0.13,0.43),P<0.00001]低于化疗对照组。结论:在中晚期NSCLC的治疗中,PD-1/PD-L1抑制剂的疗效以及安全性均优于化疗药物。
Objective:To systematically evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:CNKI,Wanfang,Pubmed and Cochrane Library database were searched by computer.Researchers extracted data from the trials and checked them,and the Cochrane bias risk assessment tool of RevMan5.3 was used to conduct risk assessment of the randomized controlled trials.Meta analysis was also performed by this software.Results:A total of 7 randomized controlled trials were included,including 3945 patients.Meta analysis results showed that PD-1/PD-L1 inhibitors were higher than the control group in the total survival period[HR=0.66,95%CI(0.61,0.72),P<0.00001],progression-free survival period[HR=0.72,95%CI(0.59,0.87),P=0.0007],and total effective rate[OR=1.91,95%CI(1.31,2.78),P=0.0007].Adverse events of any level[OR=0.32,95%CI(0.25,0.40),P<0.00001]and 3,4,5 adverse events[OR=0.23,95%CI(0.13,0.43),P<0.00001]were lower than the control group.Conclusion:In the treatment of advanced NSCLC,the efficacy and safety of PD-1/PD-L1 inhibitors were superior to that of chemotherapy.
作者
姜爱民
程宇
Jiang Aimin;Cheng Yu(Medical Oncology,Affiliated Central Hospital of Shenyang Medical College,Liaoning Shenyang 110024,China)
出处
《现代肿瘤医学》
CAS
2020年第20期3555-3560,共6页
Journal of Modern Oncology
